Home Therapy of Venous Thrombosis with Long-term LMWH versus Usual Care: Patient Satisfaction and Post-thrombotic Syndrome

American Journal of Medicine

Volumn 122, Issue 8, 2009, Pages

  Hull, Russell D ^a   Pineo, Graham F ^a   Brant, Rollin ^b   Liang, Jane ^a   Cook, Roy ^a   Solymoss, Susan ^c   Poon, Man Chiu ^a   Raskob, Gary ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Deep vein thrombosis; Leg ulcer; Post thrombotic syndrome; Tinzaparin; Warfarin

Indexed keywords

TINZAPARIN; WARFARIN;

ADULT; ARTICLE; BLEEDING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRACTURE; HOME CARE; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LEG ULCER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PATIENT SATISFACTION; POSTTHROMBOSIS SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; THROMBOCYTOPENIA;

EID: 67651177558     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.12.023     Document Type: Article

References (46)

1. Buller H.R., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 401S-428S
2. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th Edition). Chest 133 (2008) 454S-545S
3. Hull R.D., Pineo G.F., Brant R.F., et al., LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119 (2006) 1062-1072
4. Hull R.D., Pineo G.F., Brant R.F., et al., LITE Trial Investigators. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 120 (2007) 72-82
5. Kahn S.R., Kearon C., Julian J.A., et al., Extended Low-intensity Anticoagulation for Thrombo-embolism (ELATE) Investigators. Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein thrombosis. J Thromb Haemost 3 (2005) 718-723
6. Kahn S.R. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis 21 (2006) 41-48
7. Prandoni P., Lensing A.W., Prins M.H., et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med 141 (2004) 249-256
8. Prandoni P., Frulla M., Sartor D., et al. Venous abnormalities and the post-thrombotic syndrome. J Thromb Haemost 3 (2005) 401-402
9. Vedantham S. Interventional approaches to acute venous thromboembolism. Semin Respir Crit Care Med 29 (2008) 56-65
10. Hyers T.M., Agnelli G., Hull R.D., et al. Antithrombotic therapy for venous thromboembolic disease. Chest 119 1 Suppl (2001) 176S-193S
11. PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 263 (1990) 2753-2759
12. Freitas J.E., Sarosi M.G., Nagle C.C., et al. Modified PIOPED criteria used in clinical practice. J Nucl Med 36 (1995) 1573-1578
13. Stewart A.L., and Ware Jr. J.E. Measuring Functioning and Well-being: The Medical Outcomes Study Approach (1992), Duke University Press, Durham, NC
14. Koopman M.M., Prandoni P., Piovella F., et al., The Tasman Study Group. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 334 (1996) 682-687
15. Lancaster T.R., Singer D.E., Sheehan M.A., et al. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med 151 (1991) 1944-1949
16. Rodger M.A., Gagné-Rodger C., Howley H.E., et al. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy. Thromb Res 112 (2003) 13-18
17. Hedner E., Carlsson J., Kulich K.R., et al. An instrument for measuring health-related quality of life in patients with deep venous thrombosis (DVT): development and validation of Deep Venous Thrombosis Quality of Life (DVTQOL) questionnaire. Health Qual Life Outcomes 2 (2004) 30
18. Villalta S., Bagatella P., Piccioli A., et al. Assessment of validity and reproducibility of a clinical scale for the post-thrombotic syndrome [abstract]. Haemostasis 24 (1994) 158a
19. Brandjes D.P., Büller H.R., Heijboer H., et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 349 (1997) 759-762
20. Pini M., Aiello S., Manotti C., et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 72 (1994) 191-197
21. Das S.K., Cohen A.T., Edmondson R.A., et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 20 (1996) 521-526
22. Gonzalez-Fajardo J.A., Arreba E., Castrodeza J., et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 30 (1999) 283-292
23. Lopaciuk S., Bielska-Falda H., Noszczyk W., et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 81 (1999) 26-31
24. Veiga F., Escribá A., Maluenda M.P., et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 84 (2000) 559-564
25. López-Beret P., Orgaz A., Fontcuberta J., et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 33 (2001) 77-90
26. Kakkar V.V., Gebska M., Kadziola Z., et al., Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 89 (2003) 674-680
27. Daskalopoulos M.E., Daskalopoulou S.S., Tzortzis E., et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 29 (2005) 638-650
28. Lee A.Y., Levine M.N., Baker R.I., et al., Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 (2003) 146-153
29. Agnelli G., and Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis 25 (2008) 37-44
30. Rodger M.A., Kahn S.R., Wells P.S., et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 179 (2008) 417-426
31. Siragusa S., Malato A., Anastasio R., et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood 112 (2008) 511-515
32. Kyrle P.A., Minar E., Bialonczyk C., et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350 (2004) 2558-2563
33. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
34. Jaeschke R., Guyatt G.H., and Cook D. Quality of life instruments in the evaluation of new drugs. Pharmacoeconomics 1 (1992) 84-94
35. Lamping D.L., Schroter S., Kurz X., et al. Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg 37 (2003) 410-419
36. Davey H., Barratt A., Butow P., and Deeks J. A one-item question with a Likert or Visual Analog Scale adequately measured current anxiety. J Clin Epidemiol 60 (2007) 356-360
37. Rodger M.A., Kahn S.R., Le Gal G., et al. Inter-observer reliability of measures to assess the post-thrombotic syndrome. Thromb Haemost 100 (2008) 164-166
38. Kahn S.R., Shrier I., and Julian J.A. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 149 (2008) 698-707
39. Daskalopoulos M.E., Daskalopoulou S.S., Prezas L., et al. Three-year follow-up of long-term deep venous thrombosis treatment with the low molecular weight heparin tinzaparin. Angiology 25 2 Suppl 1 (2006) 76
40. Daskalopoulos M.E., Daskalopoulou S.S., and Liapis C.D. Tinzaparin in long-term treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 34 (2007) 353-354
41. Hirsh J. Heparin and low-molecular-weight heparin. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 188S-203S
42. Mousa S.A. The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Cardiovasc Drug Rev 20 (2002) 199-216
43. Kalani M., Apelqvist J., Blombäck M., et al. Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study. Diabetes Care 26 (2003) 2575-2580
44. Altman D.G., Schulz K.F., Moher D., et al. The revised CONSORT statement for reporting randomized trials: explanation and elaborations. Ann Intern Med 134 (2001) 663-694
45. Moher D., Schulz K.F., and Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. JAMA 285 (2001) 1987-1991
46. Ioannidis J.P.A., Evans S.J.W., Gotzsche P.C., et al., CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT Statement. Ann Intern Med 141 (2004) 781-788